Back

Tumor Resectability and Pathologic Response After Neoadjuvant Long-Course Chemoradiotherapy for Locally Advanced Rectal Cancer in a Resource-Limited Setting

Halake, S. S.; Bedada, H. F.; Desalegn, T. M.; Feyisa, T. B.; Tsige, K. A.; Woldetsadik, E. S.; Kantelhardt, E. J.

2026-03-27 oncology
10.64898/2026.03.25.26349327 medRxiv
Show abstract

Purpose In resource-limited settings, locally advanced rectal cancer (LARC) often presents at advanced stages. Long-course chemoradiotherapy (LCCRT) remains a cornerstone of neoadjuvant therapy, yet outcome data from such settings remain limited. This study assessed tumor resectability, pathologic response, and factors associated with resectability following neoadjuvant LCCRT at Ethiopias largest tertiary oncology center. Methods A retrospective cohort study was conducted among patients with stage II-III rectal adenocarcinoma (cT3-4 and/or cN+) who completed neoadjuvant LCCRT at Tikur Anbessa Specialized Hospital between 2018 and 2023. Tumor resectability was determined by multidisciplinary team (MDT) assessment. Multivariable logistic regression was used to identify factors associated with post-LCCRT resectability, adjusting for initial T stage, circumferential resection margin (CRM) status, histologic subtype, radiotherapy technique, and neoadjuvant regimen. Results Among 58 eligible patients (median age 45 years; 62% male), 62% had cT4 tumors, 53% had cN2 disease, and 84.5% had involved CRM. The median diagnosis-to-LCCRT interval was 64 weeks (interquartile range [IQR], 37-82). After LCCRT, 27 patients (46.6%) were deemed resectable by MDT assessment; 19 patients (32.8%) ultimately underwent curative-intent surgery (median interval from LCCRT to surgery, 10 weeks; IQR, 7-15). Initial cT3 stage was associated with higher odds of resectability (adjusted odds ratio [AOR], 6.2; 95% CI, 1.06-36.37), whereas receipt of total neoadjuvant therapy was associated with lower odds (AOR, 0.10; 95% CI, 0.02-0.49). No pathologic complete responses were observed. Conclusion In this cohort characterized by advanced disease at presentation and treatment delays, neoadjuvant LCCRT resulted in low resectability and limited pathologic response. To enhance curative potential, concerted efforts are needed to expedite the timely initiation of radiotherapy, optimize multidisciplinary team assessment, and increase surgical capacity.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 15%
12.6%
2
BMC Cancer
52 papers in training set
Top 0.1%
10.5%
3
Cancers
200 papers in training set
Top 0.4%
10.1%
4
Cancer Medicine
24 papers in training set
Top 0.1%
9.2%
5
Annals of Oncology
13 papers in training set
Top 0.1%
9.2%
50% of probability mass above
6
Frontiers in Oncology
95 papers in training set
Top 0.3%
7.2%
7
British Journal of Cancer
42 papers in training set
Top 0.3%
4.3%
8
Scientific Reports
3102 papers in training set
Top 36%
3.6%
9
npj Precision Oncology
48 papers in training set
Top 0.4%
2.1%
10
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.2%
2.1%
11
International Journal of Radiation Oncology*Biology*Physics
21 papers in training set
Top 0.2%
2.1%
12
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.2%
2.1%
13
BMJ Open
554 papers in training set
Top 9%
1.7%
14
JCO Precision Oncology
14 papers in training set
Top 0.2%
1.7%
15
European Journal of Cancer
10 papers in training set
Top 0.2%
1.5%
16
PeerJ
261 papers in training set
Top 10%
1.2%
17
International Journal of Cancer
42 papers in training set
Top 0.9%
1.1%
18
Nature Communications
4913 papers in training set
Top 57%
1.1%
19
Frontiers in Immunology
586 papers in training set
Top 6%
1.1%
20
Cancer Letters
32 papers in training set
Top 0.7%
0.8%
21
Clinical Cancer Research
58 papers in training set
Top 2%
0.8%
22
Journal of Translational Medicine
46 papers in training set
Top 3%
0.8%
23
JNCI Cancer Spectrum
10 papers in training set
Top 0.6%
0.7%
24
JAMA Network Open
127 papers in training set
Top 5%
0.6%
25
Journal of Clinical Medicine
91 papers in training set
Top 7%
0.6%
26
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 1%
0.6%
27
Diagnostics
48 papers in training set
Top 3%
0.6%
28
Radiotherapy and Oncology
18 papers in training set
Top 0.3%
0.5%
29
JCO Clinical Cancer Informatics
18 papers in training set
Top 1%
0.5%